RecruitingRecruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
NCT07775287 · Genmab
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer
About this study
This is a Phase 3, randomized, open-label, global, multicenter, interventional trial to evaluate the efficacy and safety of petosemtamab in combination with investigator's choice (IC) chemotherapy (fluorouracil + leucovorin \[calcium folinate\] + irinotecan \[FOLFIRI\] or 5-FU, leucovorin \[calcium folinate\], and oxaliplatin \[mFOLFOX6\]; Arm A) versus IC cetuximab or bevacizumab in combination with IC chemotherapy (FOLFIRI or mFOLFOX6; Arm B) as second line (2L) treatment for participants with KRAS, NRAS, and BRAF wild type (wt), recurrent, unresectable or metastatic colorectal cancer (CRC).
Eligibility criteria
Key Inclusion Criteria:
* Histologically or cytologically confirmed colorectal adenocarcinoma that is recurrent, unresectable or metastatic.
* Must have documented KRAS and NRAS wt CRC, as determined by medical record of results from local testing or as assessed by central testing. Next-generation sequencing-based test results from tumor tissue are required for determining eligibility. At a minimum, local testing must have assessed the mutational status of KRAS and NRAS G12/G13, A59, Q61, K117, and A146 codons.
* Has received no more than 1 line of prior systemic therapy for unresectable or metastatic CRC, with documented disease progression. First line (1L) regimen must be fluoropyrimidine- and oxaliplatin- (if 2L choice of backbone is FOLFIRI) or irinotecan- (if 2L choice of backbone is fluorouracil + leucovorin (calcium folinate) + oxaliplatin \[FOLFOX\]) based. Prior anti-vascular endothelial growth factor receptor (VEGF) treatment is allowed.
* Must be eligible for treatment with mFOLFOX6 (if assigned by the investigator to receive mFOLFOX6) or FOLFIRI (if assigned by the investigator to receive FOLFIRI) according to local regulatory approvals and standard of care (SOC) guidelines.
Key Exclusion Criteria:
* BRAF V600 mutation (eg, V600E) and/or microsatellite instability-high/deficient mismatch repair tumor status and/or ERBB2/human epidermal growth factor receptor 2 (HER2) positive/amplified tumor status as documented by local test results in the medical record or from central testing or known documented activating HRAS mutation identified prior to enrollment from local testing results in the medical record, if available .
* Prior exposure to any agents that target epidermal growth factor receptor (EGFR) (including but not limited to protein products, monoclonal antibodies, tyrosine kinase inhibitors, or antisense oligonucleotide therapy).
* Prior exposure to irinotecan (for participants assigned to FOLFIRI) or oxaliplatin (for participants assigned to FOLFOX) in the metastatic setting.
* Known complete dihydropyrimidine dehydrogenase (DPD) deficiency or known homozygous/compound heterozygous dihydropyrimidine dehydrogenase gene (DPYD) variants associated with complete loss of DPD activity. Testing for DPD deficiency should be performed per local guidelines.
* For a participant who is to receive FOLFIRI: known to be homozygous for the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1)\*28 or \*6 alleles or compound or double heterozygous for the UGT1A1\*28 and \*6 alleles. Testing for UGT1A1 should be done in accordance with local guidelines.
* Participants with non-colorectal adenocarcinumatous disease.
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Study design
Enrollment target: 600 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-07
Estimated completion: 2030-01-31
Last updated: 2026-11-16
Interventions
Drug: PetosemtamabDrug: CetuximabDrug: BevacizumabDrug: 5-FUDrug: Leucovorin (Calcium Folinate)Drug: OxaliplatinDrug: Irinotecan
Primary outcomes
- • Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 2.5 years)
- • Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICR (Up to approximately 2.5 years)
Sponsor
Genmab · industry
Contacts & investigators
ContactGenmab Trial Information · contact · clinicaltrials@genmab.com · +4570202728
InvestigatorStudy Official · study_director, Genmab
All locations (7)
Genesis Cancer Center Hot Springs National ParkRecruiting
Hot Springs, Arkansas, United States
Valkyrie Clinical Trials - Los AngelesRecruiting
Los Angeles, California, United States
Moffitt Cancer CenterRecruiting
Tampa, Florida, United States
Low Country Cancer Care Associates_Savannah_2Recruiting
Savannah, Georgia, United States
New York Cancer and Blood Specialists - Babylon Medical OncologyRecruiting
Babylon, New York, United States
Vista Oncology - West Olympia_Olympia_2Recruiting
Olympia, Washington, United States
PanOncologyRecruiting
Manati, Puerto Rico